Ascendis Pharma A/S (NASDAQ:ASND) Hits New 12-Month High – Time to Buy?

Ascendis Pharma A/S (NASDAQ:ASND) shares hit a new 52-week high on Friday . The stock traded as high as $157.40 and last traded at $155.51, with a volume of 179633 shares traded. The stock had previously closed at $153.14.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ASND. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. The Goldman Sachs Group raised their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Wedbush reaffirmed an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Stock Up 2.2 %

The company’s 50-day moving average price is $136.11 and its 200-day moving average price is $133.96. The firm has a market cap of $9.50 billion, a price-to-earnings ratio of -22.05 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. Analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently made changes to their positions in ASND. T. Rowe Price Investment Management Inc. boosted its stake in Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock worth $375,226,000 after purchasing an additional 960,504 shares during the last quarter. Capital International Investors boosted its position in Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock worth $394,183,000 after acquiring an additional 753,859 shares during the last quarter. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S during the third quarter worth about $60,000. RA Capital Management L.P. boosted its position in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock worth $1,392,221,000 after acquiring an additional 402,316 shares during the last quarter. Finally, Vestal Point Capital LP boosted its position in Ascendis Pharma A/S by 108.0% during the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock worth $71,588,000 after acquiring an additional 270,000 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.